ERRATA

Errata

This article corrects:

  1. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues Volume 31, Issue s1, 95–103, Article first published online: 4 January 2011

In the abstract of Papatheodoridis (1), the following statement is incorrect:

All NUCs are potent anti-hepatitis B virus agents (all except adefovir are more potent than IFN-α) with entecavir and tenofovir being the most potent. Most importantly NUCs all have minimal risk of resistance during long-term monotherapy.

The correct sentence should be:

All NUCs are potent anti-hepatitis B virus agents (all but adefovir are more potent than IFN-α) with entecavir (ETV) and tenofovir offering the highest potency and most importantly minimal to negligible risk of resistance during long-term monotherapy.

Ancillary